Phase 3 Trial for Patients with Severe-to-Critical COVID-19 Symptoms Reaches Enrollment Halfway Point
Germantown, MD, USA (August 26, 2020) – Amarex Clinical Research, LLC, an NSF International company, announced today their client’s Phase 3 clinical trial for patients with severe-to-critical COVID-19 symptoms has reached the patient enrollment halfway point. Preceding follow-up, Amarex’s statistics team will conduct the interim analysis (IA). Results from the IA are expected by mid-October.
This clinical trial investigates CytoDyn’s product leronlimab (PRO 140), a monoclonal antibody product currently undergoing tests as an IND in the treatment of multiple disease indications, including HIV/AIDS, cancer, and GVHD.
Amarex’s President & CEO, Dr. Kazem Kazempour, stated, “Our staff is working hard to expedite COVID-19 clinical trials to make treatments widely available to patients. Early last week we completed a Phase 2 trial of PRO 140 in patients with mild-to-moderate documented COVID-19 symptoms and we are encouraged by the study results. We are also working with CytoDyn to submit an IND for a Phase 3 trial of PRO 140 in long-hauler COVID-19 patients. Amarex has provided, and will continue to provide, clinical trial managements services.”
About CytoDyn Inc.
CytoDyn Inc. is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in the first quarter of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients and plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at www.cytodyn.com.
About Amarex Clinical Research, LLC, an NSF International company
Amarex Clinical Research, LLC, an NSF International company, is a global, full-service Contract Research Organization (CRO), whose leadership team has significant expertise conducting biomedical research, and whose combined experience includes the design and conduct of several hundred clinical research projects in many therapeutic indications. Amarex provides comprehensive services in Project Management (Phase I-IV, BE/BA, PK/PD), Regulatory Affairs (FDA Applications and meetings, Applications to International Health Authorities, GxP Compliance Audits), Clinical Operations, Adaptive Study Designs, Statistical Analysis, Data Management, Medical Monitoring, Safety and Pharmacovigilance, and General Consulting. Amarex can take your product through the entire approval process, from creating the regulatory approval strategy, to conducting trials, to writing the marketing approval application. Join our growing list of clients with approved products. Amarex provides high quality and cost-efficient services. For more information visit www.amarexus.com.
Book a meeting or send us a message to talk to one of our experts.